TEWKSBURY, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (ACUS.PK) today announced a $1 million payment by Cephalon, the cancellation of Cephalon’s $15 million Senior Secured Convertible Note (“Note”) and the amendment of its March and November 2008 License Agreements with Cephalon for the oncology applications of Acusphere’s Hydrophobic Drug Delivery System (“HDDS”) technology and AI-525, an intravenous formulation of celecoxib.
